Context
The dopamine transporter plays a key role in the regulation of central dopaminergic transmission, which modulates cognitive processing. Disrupted dopamine function and impaired executive processing are robust features of schizophrenia.
Objective
To examine the effect of a polymorphism in the dopamine transporter gene (the variable number of tandem repeats in the 3′ untranslated region) on brain function during executive processing in healthy volunteers and patients with schizophrenia. We hypothesized that this variation would have a different effect on prefrontal and striatal activation in schizophrenia, reflecting altered dopamine function.
Design
Case-control study.
Setting
Psychiatric research center.
Participants
Eighty-five subjects, comprising 44 healthy volunteers (18 who were 9-repeat carriers and 26 who were 10-repeat homozygotes) and 41 patients with DSM-IV schizophrenia (18 who were 9-repeat carriers and 23 who were 10-repeat homozygotes).
Main Outcome Measures
Regional brain activation during word generation relative to repetition in an overt verbal fluency task measured by functional magnetic resonance imaging. Main effects of genotype and diagnosis on activation and their interaction were estimated with analysis of variance in SPM5.
Results
Irrespective of diagnosis, the 10-repeat allele was associated with greater activation than the 9-repeat allele in the left anterior insula and right caudate nucleus. Trends for the same effect in the right insula and for greater deactivation in the rostral anterior cingulate cortex were also detected. There were diagnosis × genotype interactions in the left middle frontal gyrus and left nucleus accumbens, where the 9-repeat allele was associated with greater activation than the 10-repeat allele in patients but not controls.
Conclusions
Insular, cingulate, and striatal function during an executive task is normally modulated by variation in the dopamine transporter gene. Its effect on activation in the dorsolateral prefrontal cortex and ventral striatum is altered in patients with schizophrenia. This may reflect altered dopamine function in these regions in schizophrenia.
The dopamine transporter (DAT; SLC6A3 [GenBank DQ307031]) plays a key role in the regulation of central dopaminergic transmission by mediating dopamine reuptake from the synaptic cleft into the presynaptic terminal.1 In the mammalian brain, DAT messenger RNA is localized in cell bodies of dopaminergic neurons.2,3 Its expression is highest in synapses in the striatum, substantia nigra, and ventral tegmentum,4-6 although it is also abundant in the thalamus and in the insular, motor, posterior parietal, and posterior cingulate cortices.6,7 It is expressed in lower levels in the prefrontal, anterior cingulate, primary sensory, and occipital cortices,6-8 especially within intrasynaptic as opposed to extrasynaptic extracellular space, and the rate of dopamine uptake in these areas is relatively slow.9 In these brain regions with low levels of DAT, intracellular degradation by catechol O-methyltransferase (COMT) and uptake by nonspecific transporters such as the norepinephrine transporter may play a relatively greater role in the regulation of local dopamine availability. In these regions, DAT is mainly extrasynaptic and may primarily regulate dopamine volume transmission, the spillover of dopamine into the extrasynaptic space.10-12
The human DAT gene has a polymorphic 40–base pair (bp) variable number of tandem repeats (VNTR) in the 3′ untranslated region (DAT 3′UTR VNTR). This yields several alleles ranging from 3 to 11 copies of the 40-bp repeats, with 9 and 10 being the most common.13 Although this polymorphism does not affect protein structure,14 it may influence transcription. Four independent studies15-18 have found the 10-repeat allele to be associated with higher levels of DAT expression, although there is 1 report of lower expression19 and 1 of no association.20 This DAT 3′UTR VNTR has been previously associated with Parkinson disease,21 alcoholism,22 attention-deficit/hyperactivity disorder,23,24 and Tourette syndrome.25,26
Previous functional neuroimaging studies of memory paradigms in healthy subjects have reported an effect of DAT 3′UTR VNTR on prefrontal activation, and an additive interaction between this effect and that of a functional polymorphism for COMT (Val158Met) in prefrontal cortex.11,27-29 Nonlinear interactions between the effects of the DAT and COMT polymorphisms on hippocampal28 and striatal29 activation have also been reported in the context of reward and memory tasks, respectively.
Schizophrenia is associated with alterations in the dopaminergic input to the cerebral cortex30-34 and the striatum.35-38 The same variation in DAT activity may thus have different effects on brain function in patients with schizophrenia and healthy volunteers. The aims of the present study were to examine the influence of DAT genotype on regional brain function during a verbal fluency task and to assess the extent to which this is altered in schizophrenia. We used functional magnetic resonance imaging to study samples of healthy volunteers and patients large enough to yield subgroups of sufficient size to detect effects of the DAT 3′UTR VNTR genotype on activation. Subjects underwent imaging while they performed a phonologic verbal fluency task, which normally engages the prefrontal, insular, and cingulate cortex; the striatum; and the thalamus39-47 and is associated with impaired performance48,49 and altered prefrontal activation44,47,50-53 in patients with schizophrenia.54,55 Because they express high levels of DAT4-7 and are also engaged during verbal fluency tasks,44,46 we predicted that variation in DAT 3′UTR VNTR would modulate activation in the striatum, thalamus, and insula. Our second hypothesis was that variation in the DAT 3′UTR VNTR genotype would have a different effect in patients compared with controls in 2 areas where there is good evidence that dopamine function is perturbed in schizophrenia: the striatum35-38 and the dorsolateral prefrontal cortex.30-34 Although the prefrontal cortex does not express high levels of DAT, it is connected to the striatum via the corticothalamostriatal loop,11,27 and variation in the DAT 3′UTR VNTR genotype influences activation in the prefrontal cortex as well as the striatum.27,29 In addition, the prefrontal cortex is a robust site of altered activation in schizophrenia during verbal fluency and other cognitive tasks.30-34
A total of 85 subjects participated. All were native English speakers and gave written informed consent in accordance with protocols approved by the local research ethics committee. Patients who had a diagnosis of schizophrenia from their clinical team and met DSM-IV criteria for schizophrenia (n = 41) were recruited from the South London and Maudsley National Health Service Trust. The DSM-IV diagnosis was made by an experienced psychiatrist (including M.M.P.) using a structured diagnostic interview (Schedules for Clinical Assessment in Neuropsychiatry56 and Schedule for Affective Disorders and Schizophrenia57). When interview data were missing or incomplete, the diagnosis was determined by means of the Operational Criteria Checklist.58 The Schedules for the Assessment of Positive and Negative Symptoms were used to measure psychopathologic symptoms at the time of imaging. All patients were in a stable clinical state and had previously been treated with antipsychotic medication; however, 5 were not taking antipsychotic medication at the time of imaging. The mean duration of antipsychotic treatment was 12 years. Healthy volunteers (n = 44) had no history of mental illness and no first-degree relatives with a psychotic disorder, as assessed by the Family Interview for Genetic Studies. Subjects who met DSM-IV criteria for a substance misuse disorder were excluded.
All subjects were genotyped for DAT at 3′UTR VNTR. This yielded 18 subjects who were 9-repeat carriers (2 of whom were homozygotes) and 26 subjects who were 10-repeat homozygotes in the healthy volunteer group, and 18 who were 9-repeat carriers (2 homozygotes) and 23 who were 10-repeat homozygotes in the patient group. Fisher exact tests or χ2 tests (for categorical variables) and analysis of variance tests (for numeric variables) were calculated with SPSS version 15.0 (SPSS Inc, Chicago, Illinois) to detect demographic differences in relation to genotype, diagnosis, and their interaction. There were no significant differences (P > .05) between the patient and control groups in age, ethnicity, or handedness, but patients had a lower mean IQ, fewer years of education, and a higher proportion of males (Table 1). Within the total sample and within each diagnostic group, there were no significant differences (P > .05) between genotype subgroups in any of the demographic variables. No demographic variables showed a significant genotype × diagnosis interaction, except for sex. Within the patient group, the genotype subgroups did not differ significantly (P > .05) in total scores on the Schedule for the Assessment of Positive Symptoms (mean [SD], 6.6 [6.6]) or Schedule for the Assessment of Negative Symptoms (mean [SD], 7.8 [5.1]) scores, nor in the duration (mean [SD], 12.2 [9.5] years), dose (chlorpromazine equivalents; mean [SD], 598.8 [452.3]), or type (first or second generation) of antipsychotic medication.
DNA was extracted from blood or cheek swabs by standard methods.64 Amplification of the 3′UTR VNTR region was performed by a polymerase chain reaction using the forward primer 5′TGGCACGCACCTGAGAG3′ (melting temperature, 60.8°C) and the reverse primer 5′GGCATTGGAGGATGGGG3′ (melting temperature, 62.3°C). Its products were then separated under UV light after electrophoresis on a 3.5% agarose gel containing ethidium bromide. Genotyping was successful in 88 subjects (98%). Genotype frequencies were similar to frequencies described in the literature. The patient group was in Hardy-Weinberg equilibrium (P > .99; calculated with GENEPOP65), but the control group showed a minor deviation (P = .03), which was apparently due to the presence by chance of a rare homozygous genotype, a 6/6 repeat, in a single individual. Three subjects carrying genotypes with alleles other than the 9-repeat or the 10-repeat allele (as well as 2 subjects for whom genotype calling was unreliable) were not included in the 85-subject sample further analyzed, to reduce allelic heterogeneity.
During a “generation” condition, subjects were visually presented with a series of letters and were required to overtly articulate a word beginning with each letter. This was contrasted with a “repetition” condition in which subjects were presented with the word rest and were required to say “rest” out loud. A blocked design was used, with letter and rest cues presented in blocks of 7 events. The demands of the task were manipulated by presenting 2 different sets of letter cues, termed easy and hard.46 These had previously been shown to be associated with a significant difference in behavioral performance in healthy volunteers.46 The easy condition involved the presentation of letters that are normally associated with relatively large numbers of correct responses and relatively few errors (eg, T, B, S), whereas the hard condition involved letters associated with the generation of fewer correct words and relatively more errors (eg, N, E, G). Five blocks of rest trials alternated with 5 blocks of easy letters or hard letters, resulting in a total of 70 generation and 70 repetition trials. Verbal responses were recorded, permitting the identification of “incorrect” trials in which the subject did not generate any response or generated repetitions, derivatives, or grammatical variations of a previous word. Further details are provided in the eMethods section (http://www.archgenpsychiatry.com).44,46,66,67
T2*-weighted gradient-echo single-shot echo-planar images were acquired on a 1.5-T, neuro-optimized imaging system (IGE LX System; General Electric, Milwaukee, Wisconsin) at the Maudsley Hospital, London, England. Twelve noncontiguous axial planes (7-mm thickness, 1-mm section skip, 3.75 × 3.75-mm voxel size in plane, and 64 × 64-mm matrix size in plane) parallel to the anterior commissure–posterior commissure line were collected during 1100 milliseconds in a “clustered” acquisition (echo time, 40 milliseconds; flip angle, 70°), which permitted articulatory responses to be made when images were not being acquired, minimizing the effects of head movement on the blood oxygen level–dependent signal.46 Immediately after each acquisition, a letter was presented (remaining visible for 750 milliseconds; height, 7 cm; subtending a 0.4° field of view), and a single overt verbal response was made during the silent portion (duration, 2900 milliseconds) of each repetition (repetition time, 4000 milliseconds), with an image acquired during 1100 milliseconds. Head movement was minimized by a forehead strap. To ensure that subjects heard their responses clearly, their speech was amplified by a computer sound card and then relayed back through an acoustic magnetic resonance imaging sound system and noise-insulated headphones. Further details are provided in the eMethods section.
The effect of task load, genotype, diagnosis, and their interaction on the level of accuracy of verbal responses (measured by the number of incorrect responses during imaging) was assessed by means of a multivariate 2 × 2 × 2 analysis of variance, with diagnosis and genotype as between-subject factors and task load as a within-subject factor.
Analysis was performed with SPM5 software (http://www.fil.ion.ucl.ac.uk/spm),68 running under MATLAB 6.5 (MathWorks Inc, Sherbon, Mass). To minimize movement-related artifacts, all volumes from each subject were realigned and unwarped (by means of the first as reference resliced with sinc interpolation), normalized to a standard MNI-305 template, and spatially smoothed with an 8-mm full-width at half-maximum isotropic gaussian kernel. First, the statistical analysis of regional responses was performed in a subject-specific fashion by convolving each onset time with a synthetic hemodynamic response function. To minimize performance confounds, we modeled correct and incorrect trials separately by using an event-related model, yielding 4 experimental conditions: (1) easy generation, (2) hard generation, (3) repetition, and (4) incorrect responses. The last was excluded from the group analysis to control for effects of group differences in task performance. Correct responses among the generation events (35 events in the hard version and 35 in the easy version) were contrasted with 70 repetition events. To remove low-frequency drifts, data were high-pass filtered by using a set of discrete cosine basis functions with a cutoff period of 128 seconds. Parameter estimates were calculated for all brain voxels by means of the general linear model, and contrast images for “easy generation > repetition” and “hard generation > repetition” were computed in a subject-specific fashion. Second, the subject-specific contrast images were entered into a full-factorial 2 × 2 × 2 analysis of variance, with task load as a repeated measurement, to permit inferences at the population level.69 This allowed us to characterize the impact of the experimental task on brain activation in easy and hard conditions separately within each of the 4 experimental groups (9-repeat carrier controls, 10/10-repeat controls, 9-repeat carrier patients, and 10/10-repeat patients) and test for the main effects of diagnostic group and genotype and their interaction. We modeled task load to minimize error variance but report results for the hard and easy conditions combined. Individuals with the 9/9 allele were grouped with heterozygotes to form a group of sufficient size to be included in an analysis of variance. The t-images for each contrast at the second level were transformed into statistical parametric maps of the Z statistic. In regions where there was an a priori hypothesis, we report results that survived family-wise error (FWE) at P < .05 after small-volume correction (SVC). Regions of interest for the main effect of DAT (right and left insula, right and left thalamus, and right and left caudate nucleus) were defined by means of the automated anatomical labeling atlas70 provided in PickAtlas71,72 for SPM5. Regions of interest for the diagnosis × genotype interaction were also defined with PickAtlas, using a 10-mm-radius sphere centered on foci reported in previous studies showing effects of the DAT 3′UTR VNTR genotype (in interaction with the COMT Val158Met genotype) on activation in the left striatum (−15, 9, −9)29 and middle frontal gyrus (−38, 38, 30).27 In the rest of the brain (where we did not have a priori hypotheses), we used FWE correction across the brain at P < .05. Because no effects were detected with this threshold, we report trends evident at P < .001, uncorrected, with a cluster extent of 10 voxels, for completeness. To assess how much of the interindividual (+ error) variance in blood oxygen level–dependent activation was explained by variation in genotype, we used the ηp2 (partial eta squared) measure of effect size in SPSS, after extracting the subjects' beta-measure at the voxel of peak activation.
In regions where there was a significant effect of genotype, we assessed the potentially confounding effects of antipsychotic medication with a linear regression analysis, using duration, type (first or second generation), and dose (in chlorpromazine hydrochloride equivalents) of antipsychotic treatment as covariates. Sex was included as a covariate of no interest in the image analysis because this varied with genotype in the sample. To confirm that other demographic variables did not influence the findings, we repeated the analysis using each as a covariate of no interest.
Expectedly, there was a significant (P < .05) main effect of task demand on the number of incorrect responses (F = 50.36; P < .001), as there was for diagnosis, with patients making more errors than controls (F = 8.72; P = .004). The main effect of genotype was not significant (F = 1.10; P = .30). There was no significant interaction between task demand, diagnosis, and genotype (F = 1.18; P = .28). However, there was a trend for a diagnosis × genotype interaction (F = 3.56; P = .06), irrespective of task load, reflecting poorer performance in 10/10-repeat than 9-repeat carrier patients but the converse in healthy volunteers, especially during the hard version (Table 1).
In both diagnostic groups, word generation (irrespective of task difficulty or genotype) was associated with activation in a distributed network that included, bilaterally, the inferior frontal, insular, and dorsal anterior cingulate cortex; the caudate and the thalamus; and the left middle frontal, superior temporal, and inferior parietal cortex (FWE P < .05) (Figure 1). Conversely, repetition was associated with greater engagement of the rostral anterior cingulate gyrus, precuneus, and occipital cortex.
Main Effect of Diagnostic Group
Activation in the left inferior frontal gyrus (−44, 18, 30; Z = 3.4), anterior insula (−34, 14, 8; Z = 3.3), and frontal operculum (−36, 14, 12; Z = 3.6) was greater in patients than in healthy volunteers (P < .001, uncorrected). There were no areas more activated in healthy volunteers than in patients, and there were no between-group differences in deactivation.
Main Effect of DAT 3′UTR VNTR Genotype
Within the regions of interest, the 10/10-repeat group showed greater activation than the 9-repeat carrier group in the left insula (ηp2 = 5.6%) and in the right caudate nucleus (ηp2 = 5.4%) (right anterior insula FWE P = .02; left caudate nucleus FWE P = .03, SVC) (Figure 2 and Table 2), irrespective of diagnosis. Inspection of the parameter estimates (plotted in Figure 2A for the left insula) showed that these main effects were driven by relatively strong effects of genotype in the patient group. Also, the focus of maximal significance in the left insula (−30, 6, 16) was close to the focus of the cluster where patients showed greater activation than controls (−34, 14, 8, as noted earlier). None of the regions of interest showed greater activation in 9-repeat carriers than in 10-repeat homozygotes.
Whole-brain analysis indicated that, irrespective of diagnosis, subjects in the 10/10-repeat group showed greater activation than those in the 9-repeat carrier group (P < .001, uncorrected) in the left anterior insula (−30, 6, 16; Z = 3.5; ηp2 = 5.6%) and in a right-sided cluster focused at 26, 4, 18 (Z = 3.6; ηp2 = 6.6%) that included the right caudate (reported for the foregoing region of interest analysis) and the adjacent part of the right insula. The plot of the parameter estimates was similar to that of the left anterior insula (described in the previous paragraph; Figure 2A). There was also a trend (P < .001, uncorrected) for a main effect in the rostral part of the anterior cingulate gyrus bilaterally (−2, 40, −2; Z = 3.4; and 2, 40, −2; Z = 3.3; ηp2 = 6.7). Exploration of the parameter estimates (Figure 2B) showed that this reflected deactivation during word generation (ie, more activation during repetition than generation), which was more pronounced in the 10/10-repeat group than in the 9-repeat carrier group.
Group × Genotype Interaction
There was an interaction between the effects of diagnosis and genotype in the left middle frontal gyrus (ηp2 = 6.4%) and in the left nucleus accumbens (ηp2 = 4.8%) (left middle frontal gyrus FWE P = .05; left nucleus accumbens FEW P = .02, SVC) (Figure 3 and Table 2). In the former region, there was no statistically significant difference in activation between the DAT 3′UTR VNTR genotypes in healthy volunteers, but in patients the 9-repeat allele was associated with significantly greater activation (left middle frontal gyrus FWE P = .004, SVC; ηp2 = 21.5%). In the left nucleus accumbens, healthy volunteers with the 10/10-repeat genotype showed more activation than 9-repeat carriers, whereas the opposite applied in the patients. No other brain regions showed a diagnosis × genotype interaction (at P < .001, uncorrected).
Effects of Potentially Confounding Factors on Activation
Linear regression analysis indicated that activation in the areas where there were significant effects of DAT (either irrespective of or dependent on diagnosis) was not related to the dose, type, or duration of antipsychotic treatment, even at a very liberal statistical threshold (P = .5, uncorrected). Analyses included sex as a covariate of no interest. Repeating these analyses after covarying independently for IQ, years of education, or ethnicity did not alter the location or the Z score of the reported results.
Our hypothesis that the DAT 3′UTR VNTR genotype would influence task-related activation was confirmed in the left insula and caudate nucleus. In both of these regions, the 10-repeat allele was associated with greater activation than the 9-repeat allele in both healthy and schizophrenic subjects. A whole-brain analysis also demonstrated a trend for the same effect of genotype in the part of the right insula homologous to that identified in the region-of-interest analysis. The insula, especially in the left hemisphere, plays a major role in verbal fluency and other language-related tasks44,46,47,51 and expresses high levels of the DAT relative to other cortical areas.7 Greater insular activation in carriers of the 10-repeat allele can be interpreted in terms of the putative effects of dopamine on the “efficiency” of cortical function. According to this model, 10-repeat carriers, who have more DAT than 9-repeat carriers, remove dopamine from synapses more rapidly, reducing dopamine to a level that is suboptimal for the local signal to noise ratio, reducing the efficiency of cortical function, and leading to increased activation.31-33 This is, to our knowledge, the first evidence of an effect of the DAT 3′UTR VNTR genotype on function in the insula in humans, previous effects having been reported in the hippocampus (in interaction with COMT genotype) and in the prefrontal cortex.11,27-29 The caudate nucleus is, with the putamen, the brain area with the highest expression of DAT7 and is also implicated in verbal fluency and articulation.73-76 It is a major termination site of central dopaminergic projections from the brainstem.77 The extent to which the foregoing model of dopaminergic tuning of cortical efficiency is also applicable in the striatum is unclear.
There was a trend for the 10-repeat allele to be associated with greater deactivation during word generation than the 9-repeat allele in the rostral anterior cingulate cortex. The relatively greater engagement of this region during verbal repetition (compared with generation) may be related to its involvement in the “default” network that mediates internally generated processes during low-level baseline conditions.78-80 The more marked response in individuals with the 10/10-repeat genotype might reflect an effect of lower dopamine activity on the efficiency of cingulate cortical function during the baseline condition, although the concept of the dopaminergic modulation of efficiency is derived from studies of prefrontal cortex during working memory tasks.78-80 The direction of the DAT 3′UTR VNTR's effect on cingulate activation is the same as that of a previous report,11 although this was in a more dorsal part of the gyrus during a working memory task.
Consistent with our hypotheses about genotype × diagnosis interactions, there was an interaction in the left middle frontal gyrus. In this region, there was significantly greater activation in patients carrying the 9-repeat than the 10/10-repeat genotype but a similar response in the 2 genotype subgroups in healthy volunteers. The 9-repeat allele is associated with lower gene expression15-18 and hence weaker DAT activity and higher dopamine levels. The fact that this effect of genotype was evident in patients with schizophrenia, accounting for more than one-fifth of the interindividual variance (21.5%), but not controls, raises the possibility that the effect of the 9-repeat allele interacts with other factors contributing to the perturbation of dopamine function in the disorder. In schizophrenia, it is thought that dopamine activity is increased in the striatum but decreased in the cortex.81-84 Dopamine transporter is present at relatively low levels in the prefrontal cortex, whereas it is abundant in the striatum,4,6,85 and therefore the effects we observed in the prefrontal cortex may be secondary to effects of the DAT 3′UTR VNTR genotype in the striatum. The striatum receives dopaminergic input from the substantia nigra and the ventral tegmental area. Dopamine transporter removes dopamine from the intrasynaptic space of these terminals, reducing stimulation of dopamine receptors, which, in the striatum, are predominantly D2.86-88 Stimulation of these receptors leads to inhibitory effects on the thalamus, which then projects to the prefrontal cortex. A decrease in DAT activity associated with the 9-repeat allele may therefore increase synaptic dopamine levels and, thus, D2 stimulation in the striatum, inhibiting the thalamus and decreasing its excitatory input to the prefrontal cortex, which is thought to be necessary for an optimal signal to noise ratio in the prefrontal cortex. In schizophrenia, increased striatal dopamine activity may be amplified in patients with the 9-repeat allele, further increasing local dopamine levels and inhibition of the thalamus, leading to a marked reduction in the signal to noise ratio in prefrontal pyramidal neurons.89 This could account for the increased prefrontal activation we detected in patients with the 9-repeat allele.
A similar interaction was evident in the left nucleus accumbens. In healthy volunteers, this region was more active during verbal repetition than generation in 9-repeat carriers, but there was no difference between the conditions in subjects with the 10/10-repeat genotype. The converse applied in the patient subgroups (Table 2). As discussed in relation to the interaction in the prefrontal cortex, in schizophrenia, increased dopamine activity in the striatum may alter the impact of variation in DAT genotype on local dopamine levels, producing the opposite effect on activation in patients compared with controls.
Because antipsychotics have an antagonistic effect on central dopamine receptors and because all of our patients were receiving antipsychotic drugs, the potentially confounding effects of medication on our findings in patients with schizophrenia must be considered. Antipsychotics can modulate presynaptic dopamine up take capacity90-92 and cortical activation93 and may also affect performance of verbal fluency94,95 and other cognitive tasks,92,96,97 although these findings have not always been replicated.98 Moreover, antipsychotic medication may reduce DAT activity via blockade of D2 receptors.99 Therefore, it is possible that differences in the effect of genotype between patients and controls may have been related to effects of medication rather than an effect of schizophrenia. In view of these concerns, we examined the potential effect of dose, type, and duration of antipsychotic treatment on activation in regions where we found significant effects of genotype. There was no evidence that the effects of genotype we observed were related to effects of medication on activation in these regions. Nevertheless, the possibility that the differences in the effects of genotype in patients compared with controls were related to medication as opposed to schizophrenia cannot be excluded without repetition of the present study in medication-naive patients. However, recruiting and performing imaging in a large sample of this type would be logistically difficult.
The network of areas engaged by the verbal fluency task in the present study is consistent with that reported in several previous studies.44,46,47,51 Patients showed greater activation than healthy volunteers in the left middle frontal gyrus, frontal operculum, and anterior insula. Many previous comparisons of patients with schizophrenia and volunteers have found differences in left frontal activation during verbal fluency, although some have reported decreases and others, increases.44,47,50-53,100-103 This inconsistency may partly reflect differences in sample sizes and the degree to which the effects of impaired task performance in schizophrenia have been controlled for. The present sample was comparatively large, and the effects of differential task performance were minimized by using a paced paradigm, online monitoring of behavioral performance, and restriction of the analysis to images associated with correct responses. Greater prefrontal activation in schizophrenia during cognitive tasks after controlling for differential performance may reflect impaired prefrontal cortical efficiency.104
The effect of the DAT 3′UTR VNTR genotype on verbal fluency performance has not been investigated before, to our knowledge. Although there was no significant main effect of genotype, there was a trend for a diagnosis × genotype interaction, which reflected poorer performance of the hard condition in 10/10-repeat than in 9-repeat carrier patients but the converse in healthy volunteers. Previous studies in healthy subjects suggest that the DAT 3′UTR VNTR genotype does not influence performance on working memory tasks,11,27 but that the 10-repeat allele is associated with a higher number of commission errors during the Continuous Performance Test and with impaired selective attention and response inhibition.105 The trend for poorer verbal fluency performance in the 10/10-repeat group with schizophrenia might thus reflect an influence of the DAT 3′UTR VNTR genotype (and hence dopamine) on attention and response inhibition, both of which are involved in executing verbal fluency tasks. Because the sample size in the present study was powered to detect differences at the neurophysiologic rather than the neuropsychological level and because the task was paced (reducing task demands), it is possible that more marked effects of DAT genotype on performance would have been evident in a larger sample, using an unpaced version of the paradigm.
We cannot exclude the possibility that the effects of the DAT 3′UTR VNTR genotype were due to other polymorphisms in strong linkage disequilibrium with the 3′UTR VNTR. The latter was selected because it has been shown to have the greatest functional effect on DAT expression.15-18 We compared individuals with one or two 9-repeat alleles against those with none (10/10-repeat group) because it was difficult to recruit a sufficient number of individuals homozygous for the 9-repeat allele. This precluded examination of whether the effect of the risk allele is better described by a dominant/recessive or additive model. Although, in most subjects, IQ was assessed by means of the Wechsler Adult Intelligence Scale, different versions of this instrument were used and, in a minority of subjects, IQ was assessed by means of the Quick Test. However, previous studies have shown that the IQ estimates obtained from these scales are highly correlated.59-64 Moreover, even if using different instruments had influenced the IQ estimates, it is unlikely to have affected the results because the proportion of subjects assessed with each version was matched across genotype groups. We used an event-related approach in the image analysis, although this is not ideal for data acquired via a block design with fixed interstimulus intervals. Although we modeled correct and incorrect trials separately to minimize the potentially confounding effects of differences in performance accuracy, reaction times were not measured, so the findings could have been influenced by differences in response speed.
Correspondence: Diana P. Prata, PhD, Institute of Psychiatry, King’s College London, PO67, De Crespigny Park, London SE5 8AF, England (d.prata@iop.kcl.ac.uk).
Submitted for Publication: November 15, 2008; final revision received March 16, 2009; accepted April 17, 2009.
Author Contributions: Dr Prata had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Financial Disclosure: None reported.
Funding/Support: Dr Prata was funded by the Fundacao para a Ciencia e Tecnologia, Lisbon, Portugal. Dr Fu was supported by a Wellcome Travelling Fellowship and Dr Picchioni by a Wellcome Trust Training Fellowship.
Role of the Sponsors: The sponsors had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; and the preparation, review, or approval of the manuscript.
Additional Contributions: We thank the reviewers for their useful suggestions. Mitul Mehta, MA, PhD (Institute of Psychiatry, King's College London), provided invaluable comments.
1.Masson
JRiad
MChaudhry
FDarmon
MAïdouni
ZConrath
MGiros
BHamon
MStorm-Mathisen
JDescarries
LEl Mestikawy
S Unexpected localization of the Na
+/Cl
−-dependent-like orphan transporter, Rxt1, on synaptic vesicles in the rat central nervous system.
Eur J Neurosci 1999;11
(4)
1349- 1361
PubMedGoogle Scholar 2.Lorang
DAmara
SGSimerly
RB Cell-type-specific expression of catecholamine transporters in the rat brain.
J Neurosci 1994;14
(8)
4903- 4914
PubMedGoogle Scholar 3.Nirenberg
MJVaughan
RAUhl
GRKuhar
MJPickel
VM The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons.
J Neurosci 1996;16
(2)
436- 447
PubMedGoogle Scholar 4.Ciliax
BJHeilman
CDemchyshyn
LLPristupa
ZBInce
EHersch
SMNiznik
HBLevey
AI The dopamine transporter: immunochemical characterization and localization in brain.
J Neurosci 1995;15
(3 pt 1)
1714- 1723
PubMedGoogle Scholar 5.Sesack
SRCarr
DB Selective prefrontal cortex inputs to dopamine cells: implications for schizophrenia.
Physiol Behav 2002;77
(4-5)
513- 517
PubMedGoogle Scholar 6.Lewis
DAMelchitzky
DSSesack
SRWhitehead
REAuh
SSampson
A Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization.
J Comp Neurol 2001;432
(1)
119- 136
PubMedGoogle Scholar 7.Wang
GJVolkow
NDFowler
JSDing
YSLogan
JGatley
SJMacGregor
RRWolf
AP Comparison of two PET radioligands for imaging extrastriatal dopamine transporters in human brain.
Life Sci 1995;57
(14)
PL187- PL191
PubMedGoogle Scholar 8.Sesack
SRHawrylak
VAGuido
MALevey
AI Cellular and subcellular localization of the dopamine transporter in rat cortex.
Adv Pharmacol 1998;42171- 174
PubMedGoogle Scholar 9.Wayment
HKSchenk
JOSorg
BA Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition.
J Neurosci 2001;21
(1)
35- 44
PubMedGoogle Scholar 11.Bertolino
ABlasi
GLatorre
VRubino
VRampino
ASinibaldi
LCaforio
GPetruzzella
VPizzuti
AScarabino
TNardini
MWeinberger
DRDallapiccola
B Additive effects of genetic variation in dopamine regulating genes on working memory cortical activity in human brain.
J Neurosci 2006;26
(15)
3918- 3922
PubMedGoogle Scholar 12.Tunbridge
EMHarrison
PJWeinberger
DR Catechol-
o-methyltransferase, cognition, and psychosis: Val
158Met and beyond.
Biol Psychiatry 2006;60
(2)
141- 151
PubMedGoogle Scholar 13.Vandenbergh
DJPersico
AMHawkins
ALGriffin
CALi
XJabs
EWUhl
GR Human dopamine transporter gene (
DAT1) maps to chromosome 5p15.3 and displays a VNTR.
Genomics 1992;14
(4)
1104- 1106
PubMedGoogle Scholar 14.Vandenbergh
DJThompson
MDCook
EHBendahhou
ENguyen
TKrasowski
MDZarrabian
DComings
DSellers
EMTyndale
RFGeorge
SRO’Dowd
BFUhl
GR Human dopamine transporter gene: coding region conservation among normal, Tourette's disorder, alcohol dependence and attention-deficit hyperactivity disorder populations.
Mol Psychiatry 2000;5
(3)
283- 292
PubMedGoogle Scholar 15.Fuke
SSuo
STakahashi
NKoike
HSasagawa
NIshiura
S The VNTR polymorphism of the human dopamine transporter (
DAT1) gene affects gene expression.
Pharmacogenomics J 2001;1
(2)
152- 156
PubMedGoogle Scholar 16.Mill
JAsherson
PBrowes
CD’Souza
UCraig
I Expression of the dopamine transporter gene is regulated by the 3′UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR.
Am J Med Genet 2002;114
(8)
975- 979
PubMedGoogle Scholar 17.Heinz
AGoldman
DJones
DWPalmour
RHommer
DGorey
JGLee
KSLinnoila
MWeinberger
DR Genotype influences in vivo dopamine transporter availability in human striatum.
Neuropsychopharmacology 2000;22
(2)
133- 139
PubMedGoogle Scholar 18.VanNess
SHOwens
MJKilts
CD The variable number of tandem repeats element in
DAT1 regulates
in vitro dopamine transporter density.
BMC Genet 2005;655
PubMed10.1186/1471-2156-6-55
Google Scholar 19.van Dyck
CHMalison
RTJacobsen
LKSeibyl
JPStaley
JKLaruelle
MBaldwin
RMInnis
RBGelernter
J Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene.
J Nucl Med 2005;46
(5)
745- 751
PubMedGoogle Scholar 20.Martinez
DGelernter
JAbi-Dargham
Avan Dyck
CHKegeles
LInnis
RBLaruelle
M The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans.
Neuropsychopharmacology 2001;24
(5)
553- 560
PubMedGoogle Scholar 21.Le Couteur
DGLeighton
PW McCann
SJPond
S Association of a polymorphism in the dopamine-transporter gene with Parkinson's disease.
Mov Disord 1997;12
(5)
760- 763
PubMedGoogle Scholar 22.Muramatsu
THiguchi
S Dopamine transporter gene polymorphism and alcoholism.
Biochem Biophys Res Commun 1995;211
(1)
28- 32
PubMedGoogle Scholar 23.Gill
MDaly
GHeron
SHawi
ZFitzgerald
M Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism.
Mol Psychiatry 1997;2
(4)
311- 313
PubMedGoogle Scholar 24.Faraone
SVPerlis
RHDoyle
AESmoller
JWGoralnick
JJHolmgren
MASklar
P Molecular genetics of attention-deficit/hyperactivity disorder.
Biol Psychiatry 2005;57
(11)
1313- 1323
PubMedGoogle Scholar 25.Díaz-Anzaldúa
AJoober
RRiviere
JBDion
YLespérance
PRicher
FChouinard
SRouleau
GAMontreal Tourette Syndrome Study Group, Tourette syndrome and dopaminergic genes: a family-based association study in the French Canadian founder population.
Mol Psychiatry 2004;9
(3)
272- 277
PubMedGoogle Scholar 26.Comings
DEWu
SChiu
CRing
RHGade
RAhn
CMacMurray
JPDietz
GMuhleman
D Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorder: the additive and subtractive effect of the three dopaminergic genes—DRD2, D beta H, and DAT1.
Am J Med Genet 1996;67
(3)
264- 288
PubMedGoogle Scholar 27.Caldú
XVendrell
PBartres-Faz
DClemente
IBargalló
NJurado
MASerra-Grabulosa
JMJunqué
C Impact of the COMT Val108/158 Met and DAT genotypes on prefrontal function in healthy subjects.
Neuroimage 2007;37
(4)
1437- 1444
PubMedGoogle Scholar 28.Bertolino
ADi Giorgio
ABlasi
GSambataro
FCaforio
GSinibaldi
LLatorre
VRampino
ATaurisano
PFazio
LRomano
RDouzgou
SPopolizio
TKolachana
BNardini
MWeinberger
DRDallapiccola
B Epistasis between dopamine regulating genes identifies a nonlinear response of the human hippocampus during memory tasks.
Biol Psychiatry 2008;64
(3)
226- 234
PubMedGoogle Scholar 29.Yacubian
JSommer
TSchroeder
KGläscher
JKalisch
RLeuenberger
BBraus
DFBüchel
C Gene-gene interaction associated with neural reward sensitivity.
Proc Natl Acad Sci U S A 2007;104
(19)
8125- 8130
PubMedGoogle Scholar 30.Akil
MKolachana
BSRothmond
DAHyde
TMWeinberger
DRKleinman
JE Catechol-
O-methyltransferase genotype and dopamine regulation in the human brain.
J Neurosci 2003;23
(6)
2008- 2013
PubMedGoogle Scholar 31.Weinberger
DRBerman
KFChase
TN Mesocortical dopaminergic function and human cognition.
Ann N Y Acad Sci 1988;537330- 338
PubMedGoogle Scholar 32.Weinberger
DREgan
MFBertolino
ACallicott
JHMattay
VSLipska
BKBerman
KFGoldberg
TE Prefrontal neurons and the genetics of schizophrenia.
Biol Psychiatry 2001;50
(11)
825- 844
PubMedGoogle Scholar 33.Abi-Dargham
AMawlawi
OLombardo
IGil
RMartinez
DHuang
YHwang
DRKeilp
JKochan
LVan Heertum
RGorman
JMLaruelle
M Prefrontal dopamine D
1 receptors and working memory in schizophrenia.
J Neurosci 2002;22
(9)
3708- 3719
PubMedGoogle Scholar 34.Akil
MPierri
JNWhitehead
REEdgar
CLMohila
CSampson
ARLewis
DA Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects.
Am J Psychiatry 1999;156
(10)
1580- 1589
PubMedGoogle Scholar 35.Meyer-Lindenberg
AMiletich
RSKohn
PDEsposito
GCarson
REQuarantelli
MWeinberger
DRBerman
KF Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia.
Nat Neurosci 2002;5
(3)
267- 271
PubMedGoogle Scholar 36.Bertolino
ABreier
ACallicott
JHAdler
CMattay
VSShapiro
MFrank
JAPickar
DWeinberger
DR The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia.
Neuropsychopharmacology 2000;22
(2)
125- 132
PubMedGoogle Scholar 37.Grace
AA Gating of information flow within the limbic system and the pathophysiology of schizophrenia.
Brain Res Brain Res Rev 2000;31
(2-3)
330- 341
PubMedGoogle Scholar 38.Laruelle
M The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies.
Brain Res Brain Res Rev 2000;31
(2-3)
371- 384
PubMedGoogle Scholar 39.Yetkin
FZHammeke
TASwanson
SJMorris
GLMueller
WM McAuliffe
TLHaughton
VM A comparison of functional MR activation patterns during silent and audible language tasks.
AJNR Am J Neuroradiol 1995;16
(5)
1087- 1092
PubMedGoogle Scholar 40.Lurito
JTKareken
DALowe
MJChen
SHMathews
VP Comparison of rhyming and word generation with FMRI.
Hum Brain Mapp 2000;10
(3)
99- 106
PubMedGoogle Scholar 41.Hutchinson
MSchiffer
WJoseffer
SLiu
ASchlosser
RDikshit
SGoldberg
EBrodie
JD Task-specific deactivation patterns in functional magnetic resonance imaging.
Magn Reson Imaging 1999;17
(10)
1427- 1436
PubMedGoogle Scholar 42.Friedman
LKenny
JTWise
ALWu
DStuve
TAMiller
DAJesberger
JALewin
JS Brain activation during silent word generation evaluated with functional MRI.
Brain Lang 1998;64
(2)
231- 256
PubMedGoogle Scholar 43.Schlösser
RHutchinson
MJoseffer
SRusinek
HSaarimaki
AStevenson
JDewey
SLBrodie
JD Functional magnetic resonance imaging of human brain activity in a verbal fluency task.
J Neurol Neurosurg Psychiatry 1998;64
(4)
492- 498
PubMedGoogle Scholar 44.Curtis
VABullmore
ETBrammer
MJWright
ICWilliams
SCMorris
RGSharma
TSMurray
RM McGuire
PK Attenuated frontal activation during a verbal fluency task in patients with schizophrenia.
Am J Psychiatry 1998;155
(8)
1056- 1063
PubMedGoogle Scholar 45.Phelps
EAHyder
FBlamire
AMShulman
RG FMRI of the prefrontal cortex during overt verbal fluency.
Neuroreport 1997;8
(2)
561- 565
PubMedGoogle Scholar 46.Fu
CHMorgan
KSuckling
JWilliams
SCAndrew
CVythelingum
GN McGuire
PK A functional magnetic resonance imaging study of overt letter verbal fluency using a clustered acquisition sequence: greater anterior cingulate activation with increased task demand.
Neuroimage 2002;17
(2)
871- 879
PubMedGoogle Scholar 47.Yurgelun-Todd
DAWaternaux
CMCohen
BMGruber
SAEnglish
CDRenshaw
PF Functional magnetic resonance imaging of schizophrenic patients and comparison subjects during word production.
Am J Psychiatry 1996;153
(2)
200- 205
PubMedGoogle Scholar 48.Allen
HALiddle
PFFrith
CD Negative features, retrieval processes and verbal fluency in schizophrenia.
Br J Psychiatry 1993;163769- 775
PubMedGoogle Scholar 49.Howanitz
ECicalese
CHarvey
PD Verbal fluency and psychiatric symptoms in geriatric schizophrenia.
Schizophr Res 2000;42
(3)
167- 169
PubMedGoogle Scholar 50.Frith
CDFriston
KJHerold
SSilbersweig
DFletcher
PCahill
CDolan
RJFrackowiak
RSLiddle
PF Regional brain activity in chronic schizophrenic patients during the performance of a verbal fluency task.
Br J Psychiatry 1995;167
(3)
343- 349
PubMedGoogle Scholar 51.Fletcher
PCFrith
CDGrasby
PMFriston
KJDolan
RJ Local and distributed effects of apomorphine on fronto-temporal function in acute unmedicated schizophrenia.
J Neurosci 1996;16
(21)
7055- 7062
PubMedGoogle Scholar 52.Fu
CHSuckling
JWilliams
SCAndrew
CMVythelingum
GN McGuire
PK Effects of psychotic state and task demand on prefrontal function in schizophrenia: an fMRI study of overt verbal fluency.
Am J Psychiatry 2005;162
(3)
485- 494
PubMedGoogle Scholar 53.Artiges
EMartinot
JLVerdys
MAttar-Levy
DMazoyer
BTzourio
NGiraud
MJPaillère-Martinot
ML Altered hemispheric functional dominance during word generation in negative schizophrenia.
Schizophr Bull 2000;26
(3)
709- 721
PubMedGoogle Scholar 54.Broome
MRMatthiasson
PFusar-Poli
PWoolley
JBJohns
LCTabraham
PBramon
EValmaggia
LWilliams
SCBrammer
MJChitnis
X McGuire
PK Neural correlates of executive function and working memory in the “at-risk mental state.”
Br J Psychiatry 2009;194
(1)
25- 33
PubMedGoogle Scholar 55.Gur
REKeshavan
MSLawrie
SM Deconstructing psychosis with human brain imaging.
Schizophr Bull 2007;33
(4)
921- 931
PubMedGoogle Scholar 56.Wing
JKBabor
TBrugha
TBurke
JCooper
JEGiel
RJablenski
ARegier
DSartorius
N SCAN: Schedules for Clinical Assessment in Neuropsychiatry.
Arch Gen Psychiatry 1990;47
(6)
589- 593
PubMedGoogle Scholar 57.Endicott
JSpitzer
RL A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia.
Arch Gen Psychiatry 1978;35
(7)
837- 844
PubMedGoogle Scholar 58. McGuffin
PFarmer
AHarvey
I A polydiagnostic application of operational criteria in studies of psychotic illness: development and reliability of the OPCRIT system.
Arch Gen Psychiatry 1991;48
(8)
764- 770
PubMedGoogle Scholar 59.Wechsler
D Wechsler Adult Intelligence Scale—Third Edition Manual. San Antonio, TX Psychological Corp1997;
60.Wechsler
D Manual for the Wechsler Intelligence Scale—Revised. San Antonio, TX Psychological Corp1981;
61.Wechsler
D Wechsler Abbreviated Scale of Intelligence. San Antonio, TX Psychological Corp1999;
62.Ammons
RBAmmons
CH Quick Test. Missoula, MT Psychological Test Specialists1962;
63.Frith
CDLeary
JCahill
CJohnstone
EC Performance on psychological tests: demographic and clinical correlates of the results of these tests.
Br J Psychiatry Suppl 1991;
(13)
26- 29, 44-46
PubMedGoogle Scholar 64.Freeman
BSmith
NCurtis
CHuckett
LMill
JCraig
IW DNA from buccal swabs recruited by mail: evaluation of storage effects on long-term stability and suitability for multiplex polymerase chain reaction genotyping.
Behav Genet 2003;33
(1)
67- 72
PubMedGoogle Scholar 65.Raymond
MRousset
F GENEPOP (version 1.2): population genetics software for exact tests and ecumenicism.
J Hered 1995;86
(3)
248- 249
Google Scholar 66.Benton
ALHamsher
KD Multilingual Aphasia Examination. New York, NY Oxford University Press1994;
67.Lezak
MD Neuropsychological Assessment. 3rd ed. New York, NY Oxford University Press1995;
68.Friston
KJ Introduction: experimental design and statistical parametric mapping. Frackowiak
RSFriston
KJFrith
CDDolan
RJPrice
CJZeki
S
Human Brain Function. 2nd ed. New York, NY Academic Press2003;
Google Scholar 69.Penny
WDHolmes
APFriston
KJ Random effects analysis. Frackowiak
RSFriston
KJFrith
CDDolan
RJPrice
CJZeki
S
Human Brain Function. 2nd ed. New York, NY Academic Press2003;
Google Scholar 70.Tzourio-Mazoyer
NLandeau
BPapathanassiou
DCrivello
FEtard
ODelcroix
NMazoyer
BJoliot
M Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain.
Neuroimage 2002;15
(1)
273- 289
PubMedGoogle Scholar 71.Maldjian
JALaurienti
PJKraft
RABurdette
JH An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets.
Neuroimage 2003;19
(3)
1233- 1239
PubMedGoogle Scholar 72.Maldjian
JALaurienti
PJBurdette
JH Precentral gyrus discrepancy in electronic versions of the Talairach atlas.
Neuroimage 2004;21
(1)
450- 455
PubMedGoogle Scholar 73.Pickett
ERKuniholm
EProtopapas
AFriedman
JLieberman
P Selective speech motor, syntax and cognitive deficits associated with bilateral damage to the putamen and the head of the caudate nucleus: a case study.
Neuropsychologia 1998;36
(2)
173- 188
PubMedGoogle Scholar 74.Murphy
KCorfield
DRGuz
AFink
GRWise
RJHarrison
JAdams
L Cerebral areas associated with motor control of speech in humans.
J Appl Physiol 1997;83
(5)
1438- 1447
PubMedGoogle Scholar 75.Fabbro
FClarici
ABava
A Effects of left basal ganglia lesions on language production.
Percept Mot Skills 1996;82
(3 pt 2)
1291- 1298
PubMedGoogle Scholar 76.Speedie
LJWertman
ETa’ir
JHeilman
KM Disruption of automatic speech following a right basal ganglia lesion.
Neurology 1993;43
(9)
1768- 1774
PubMedGoogle Scholar 77.Lindvall
OBjorklund
A Anatomy of the dopaminergic neuron systems in the rat brain.
Adv Biochem Psychopharmacol 1978;191- 23
PubMedGoogle Scholar 78.Binder
JRFrost
JAHammeke
TABellgowan
PSRao
SMCox
RW Conceptual processing during the conscious resting state: a functional MRI study.
J Cogn Neurosci 1999;11
(1)
80- 95
PubMedGoogle Scholar 79. McKiernan
KAKaufman
JNKucera-Thompson
JBinder
JR A parametric manipulation of factors affecting task-induced deactivation in functional neuroimaging.
J Cogn Neurosci 2003;15
(3)
394- 408
PubMedGoogle Scholar 80. McKiernan
KAD’Angelo
BRKaufman
JNBinder
JR Interrupting the “stream of consciousness”: an fMRI investigation.
Neuroimage 2006;29
(4)
1185- 1191
PubMedGoogle Scholar 81.Breier
ASu
TPSaunders
RCarson
REKolachana
BSde Bartolomeis
AWeinberger
DRWeisenfeld
NMalhotra
AKEckelman
WCPickar
D Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.
Proc Natl Acad Sci U S A 1997;94
(6)
2569- 2574
PubMedGoogle Scholar 82.Abi-Dargham
AGil
RKrystal
JBaldwin
RMSeibyl
JPBowers
Mvan Dyck
CHCharney
DSInnis
RBLaruelle
M Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.
Am J Psychiatry 1998;155
(6)
761- 767
PubMedGoogle Scholar 83.Laruelle
MAbi-Dargham
A Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies.
J Psychopharmacol 1999;13
(4)
358- 371
PubMedGoogle Scholar 84.Laruelle
MAbi-Dargham
AGil
RKegeles
LInnis
R Increased dopamine transmission in schizophrenia: relationship to illness phases.
Biol Psychiatry 1999;46
(1)
56- 72
PubMedGoogle Scholar 85.Sesack
SRPickel
VM Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area.
J Comp Neurol 1992;320
(2)
145- 160
PubMedGoogle Scholar 86.Weiner
DMLevey
AISunahara
RKNiznik
HBO’Dowd
BFSeeman
PBrann
MR D
1 and D
2 dopamine receptor mRNA in rat brain.
Proc Natl Acad Sci U S A 1991;88
(5)
1859- 1863
PubMedGoogle Scholar 87.Camps
MCortes
RGueye
BProbst
APalacios
JM Dopamine receptors in human brain: autoradiographic distribution of D
2 sites.
Neuroscience 1989;28
(2)
275- 290
PubMedGoogle Scholar 88.Cortés
RGueye
BPazos
AProbst
APalacios
JM Dopamine receptors in human brain: autoradiographic distribution of D
1 sites.
Neuroscience 1989;28
(2)
263- 273
PubMedGoogle Scholar 89.Tanaka
S Dopaminergic control of working memory and its relevance to schizophrenia: a circuit dynamics perspective.
Neuroscience 2006;139
(1)
153- 171
PubMedGoogle Scholar 90.Gründer
GVernaleken
IMüller
MJDavids
EHeydari
NBuchholz
HGBartenstein
PMunk
OLStoeter
PWong
DFGjedde
ACumming
P Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo.
Neuropsychopharmacology 2003;28
(4)
787- 794
PubMedGoogle Scholar 91.Vernaleken
IKumakura
YCumming
PBuchholz
HGSiessmeier
TStoeter
PMüller
MJBartenstein
PGründer
G Modulation of [
18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge.
Neuroimage 2006;30
(4)
1332- 1339
PubMedGoogle Scholar 92.Vernaleken
IKumakura
YBuchholz
HGSiessmeier
THilgers
RDBartenstein
PCumming
PGründer
G Baseline [
18F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: a positron emission tomography study in healthy subjects.
Neuroimage 2008;40
(3)
1222- 1231
PubMedGoogle Scholar 93.Honey
GDBullmore
ETSoni
WVaratheesan
MWilliams
SCSharma
T Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia.
Proc Natl Acad Sci U S A 1999;96
(23)
13432- 13437
PubMedGoogle Scholar 94.Lee
MAJayathilake
KMeltzer
HY A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia.
Schizophr Res 1999;37
(1)
1- 11
PubMedGoogle Scholar 95.Hagger
CBuckley
PKenny
JTFriedman
LUbogy
DMeltzer
HY Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.
Biol Psychiatry 1993;34
(10)
702- 712
PubMedGoogle Scholar 96.Lee
MAThompson
PAMeltzer
HY Effects of clozapine on cognitive function in schizophrenia.
J Clin Psychiatry 1994;55
((suppl B))
82- 87
PubMedGoogle Scholar 97.Vernaleken
IBuchholz
HGKumakura
YSiessmeier
TStoeter
PBartenstein
PCumming
PGründer
G “Prefrontal” cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: an exploratory [
18F]-fluoro-L-DOPA-PET investigation.
Hum Brain Mapp 2007;28
(10)
931- 939
PubMedGoogle Scholar 98.Meltzer
HY McGurk
SR The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.
Schizophr Bull 1999;25
(2)
233- 255
PubMedGoogle Scholar 99.Kimmel
HLJoyce
ARCarroll
FIKuhar
MJ Dopamine D
1 and D
2 receptors influence dopamine transporter synthesis and degradation in the rat.
J Pharmacol Exp Ther 2001;298
(1)
129- 140
PubMedGoogle Scholar 100.Stevens
AAGoldman-Rakic
PSGore
JCFulbright
RKWexler
BE Cortical dysfunction in schizophrenia during auditory word and tone working memory demonstrated by functional magnetic resonance imaging.
Arch Gen Psychiatry 1998;55
(12)
1097- 1103
PubMedGoogle Scholar 101.Crespo-Facorro
BParadiso
SAndreasen
NCO’Leary
DSWatkins
GLBoles Ponto
LLHichwa
RD Recalling word lists reveals “cognitive dysmetria” in schizophrenia: a positron emission tomography study.
Am J Psychiatry 1999;156
(3)
386- 392
PubMedGoogle Scholar 102.Lewis
DAHayes
TLLund
JSOeth
KM Dopamine and the neural circuitry of primate prefrontal cortex: implications for schizophrenia research.
Neuropsychopharmacology 1992;6
(2)
127- 134
PubMedGoogle Scholar 103.Spence
SALiddle
PFStefan
MDHellewell
JSSharma
TFriston
KJHirsch
SRFrith
CDMurray
RMDeakin
JFGrasby
PM Functional anatomy of verbal fluency in people with schizophrenia and those at genetic risk: focal dysfunction and distributed disconnectivity reappraised.
Br J Psychiatry 2000;17652- 60
PubMedGoogle Scholar 104.Winterer
GWeinberger
DR Genes, dopamine and cortical signal-to-noise ratio in schizophrenia.
Trends Neurosci 2004;27
(11)
683- 690
PubMedGoogle Scholar 105.Cornish
KMManly
TSavage
RSwanson
JMorisano
DButler
NGrant
CCross
GBentley
LHollis
CP Association of the dopamine transporter (DAT1) 10/10-repeat genotype with ADHD symptoms and response inhibition in a general population sample.
Mol Psychiatry 2005;10
(7)
686- 698
PubMedGoogle Scholar